Signaturefd LLC Has $232,000 Stock Position in Exelixis, Inc. (NASDAQ:EXEL)

Signaturefd LLC increased its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 13.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 6,959 shares of the biotechnology company’s stock after buying an additional 821 shares during the quarter. Signaturefd LLC’s holdings in Exelixis were worth $232,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in EXEL. Victory Capital Management Inc. raised its position in shares of Exelixis by 16.6% during the third quarter. Victory Capital Management Inc. now owns 136,178 shares of the biotechnology company’s stock worth $3,534,000 after purchasing an additional 19,372 shares during the period. CIBC Asset Management Inc acquired a new stake in Exelixis during the 3rd quarter worth approximately $227,000. Natixis Advisors LLC lifted its stake in Exelixis by 26.2% in the third quarter. Natixis Advisors LLC now owns 29,113 shares of the biotechnology company’s stock valued at $755,000 after buying an additional 6,051 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Exelixis in the third quarter valued at approximately $1,972,000. Finally, Advisors Asset Management Inc. increased its position in shares of Exelixis by 3.2% during the third quarter. Advisors Asset Management Inc. now owns 19,853 shares of the biotechnology company’s stock worth $515,000 after acquiring an additional 609 shares in the last quarter. 85.27% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on EXEL shares. Barclays upped their target price on shares of Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Bank of America downgraded Exelixis from a “buy” rating to a “neutral” rating and upped their price target for the stock from $35.00 to $39.00 in a research report on Tuesday, December 17th. Brookline Capital Management began coverage on shares of Exelixis in a report on Monday, December 23rd. They issued a “buy” rating on the stock. UBS Group increased their target price on shares of Exelixis from $30.00 to $34.00 and gave the stock a “neutral” rating in a report on Tuesday, January 28th. Finally, StockNews.com upgraded shares of Exelixis from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 19th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $37.59.

Insider Buying and Selling

In other Exelixis news, CFO Christopher J. Senner sold 29,314 shares of Exelixis stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $36.14, for a total value of $1,059,407.96. Following the completion of the sale, the chief financial officer now owns 779,607 shares in the company, valued at $28,174,996.98. The trade was a 3.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Patrick J. Haley sold 52,636 shares of the stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the transaction, the executive vice president now owns 303,310 shares in the company, valued at approximately $11,216,403.80. The trade was a 14.79 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 140,343 shares of company stock valued at $5,177,234. Insiders own 2.85% of the company’s stock.

Exelixis Price Performance

EXEL stock opened at $36.96 on Friday. Exelixis, Inc. has a one year low of $20.14 and a one year high of $40.02. The stock has a market cap of $10.34 billion, a price-to-earnings ratio of 20.88, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57. The company has a fifty day moving average price of $35.61 and a two-hundred day moving average price of $32.82.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a net margin of 24.04% and a return on equity of 23.52%. Research analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.